scispace - formally typeset
Journal ArticleDOI

Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment

Inês Falcão-Pires, +1 more
- 01 May 2012 - 
- Vol. 17, Iss: 3, pp 325-344
TLDR
Some of the molecular and cellular pathophysiologic mechanisms, structural changes, and therapeutic strategies that may help struggle against diabetic cardiomyopathy are elucidated.
Abstract
Diabetes mellitus is an important and prevalent risk factor for congestive heart failure. Diabetic cardiomyopathy has been defined as ventricular dysfunction that occurs in diabetic patients independent of a recognized cause such as coronary artery disease or hypertension. The disease course consists of a hidden subclinical period, during which cellular structural insults and abnormalities lead initially to diastolic dysfunction, later to systolic dysfunction, and eventually to heart failure. Left ventricular hypertrophy, metabolic abnormalities, extracellular matrix changes, small vessel disease, cardiac autonomic neuropathy, insulin resistance, oxidative stress, and apoptosis are the most important contributors to diabetic cardiomyopathy onset and progression. Hyperglycemia is a major etiological factor in the development of diabetic cardiomyopathy. It increases the levels of free fatty acids and growth factors and causes abnormalities in substrate supply and utilization, calcium homeostasis, and lipid metabolism. Furthermore, it promotes excessive production and release of reactive oxygen species, which induces oxidative stress leading to abnormal gene expression, faulty signal transduction, and cardiomyocytes apoptosis. Stimulation of connective tissue growth factor, fibrosis, and the formation of advanced glycation end-products increase the stiffness of the diabetic hearts. Despite all the current information on diabetic cardiomyopathy, translational research is still scarce due to limited human myocardial tissue and most of our knowledge is extrapolated from animals. This paper aims to elucidate some of the molecular and cellular pathophysiologic mechanisms, structural changes, and therapeutic strategies that may help struggle against diabetic cardiomyopathy.

read more

Citations
More filters
Journal ArticleDOI

Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations

TL;DR: This review considers the mechanisms, history, controversies, new pharmacological agents, and recent evidence for current guidelines for cardiovascular management in the patient with diabetes mellitus to support evidence-based care outside of the acute care setting.
Journal Article

Diastolic Heart Failure

TL;DR: In this paper, a 78-year-old woman with a history of hypertension is admitted to the hospital with congestive heart failure, and physical examination reveals a blood pressure of 180/90 mm Hg, increased jugular venous pressure, peripheral edema and pulmonary rales.
Journal ArticleDOI

Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy

TL;DR: A surge in diabetic cardiomyopathy research is highlighted, current understanding of the molecular mechanisms underpinning this condition is summarized, and potential preventive and therapeutic strategies are explored.
Journal ArticleDOI

NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model

TL;DR: NLRP3 inflammasome contributed to the development of diabetic cardiomyopathy and gene silencing therapy ameliorated cardiac inflammation, pyroptosis, fibrosis and cardiac function.
Journal ArticleDOI

Curcumin Alleviates Diabetic Cardiomyopathy in Experimental Diabetic Rats

TL;DR: It is suggested that curcumin may have great therapeutic potential in the treatment of DCM, and perhaps other cardiovascular disorders, by attenuating fibrosis, oxidative stress, inflammation and cell death.
References
More filters
Journal ArticleDOI

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

TL;DR: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia, with the lowest risk being in those with HbA1c values in the normal range (<6.0%).
Journal ArticleDOI

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI

Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

TL;DR: This report supports earlier predictions of the epidemic nature of diabetes in the world during the first quarter of the 21st century and provides a provisional picture of the characteristics of the diabetes epidemic.
Related Papers (5)